Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S. (1st March 2022)

• Record Type: Journal Article
• Authors: Wang, Tong‐Hong; Leu, Yann‐Lii; Chen, Chin‐Chuan; Li, Hsin‐Jung; Yang, Shuenn‐Chen; Huang, Kuo‐Yen; Chen, Chi‐Yuan
• Is Part Of: Phytotherapy research. Volume 36:Number 5(2022)
• Page Start: 2116
• Page End: 2126
• Publication Date: 2022-03-01
• Subjects: drug resistance -- EGFR -- lung cancer -- psorachromene -- Psoralea corylifolia; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.7432
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract: The extracts from Psoralea corylifolia Linn. ( P. corylifolia ) seeds have been shown to display antitumor activity. To date, the prospects of this plant and its active compounds in the treatment of non‐small‐cell lung cancer (NSCLC) have not been thoroughly studied. In this study, we identified a novel psorachromene compound that displays selective cytotoxic effects on all NSCLC cells tested, including NSCLC cells harboring epidermal growth factor receptor (EGFR) activation mutants (H1975 L858R/T790M and H1975‐MS35 L858R/T790M/C797S ). Psorachromene induces G1 arrest in NSCLC cells harboring wild‐type EGFR but induces apoptosis in NSCLC cells harboring activating EGFR mutations. Psorachromene inhibits activated EGFR signaling and kinase activity and suppresses tumor growth of implanted H1975‐MS35 L858R/T790M/C797S cells in nude mice. Molecular docking analysis revealed that psorachromene could form stronger bonds with mutant EGFR than wild‐type EGFR, which might account for the greater cytotoxic effects observed in NSCLC cells harboring activating EGFR mutations (H1975 and H1975‐MS35) than wild‐type EGFR (A549). In conclusion, it is suggested that psorachromene is an attractive agent to be further explored for its use in the treatment of NSCLC patients harboring EGFR L858R/T790M/C797S.